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ABSTRACT
Introduction: Latanoprostene bunod is a novel
nitric oxide (NO)-donating prostaglandin F2a
receptor agonist in clinical development for the
reduction of intraocular pressure (IOP) in
patients with open-angle glaucoma or ocular
hypertension. We evaluated the effect of
latanoprostene bunod 0.024% instilled once
daily (QD) on lowering IOP over a 24-h period
in healthy Japanese subjects following 14 days
of treatment.
Methods: This was a single-arm, single-center,
open-label clinical study of 24 healthy Japanese
male volunteers. A baseline IOP profile was
established in both eyes in the sitting position
at 8 PM, 10 PM, 12 AM, 2 AM, 4 AM, 8 AM,
10 AM, 12 PM, and 4 PM using a Goldmann
applanation tonometer. Subjects subsequently
instilled latanoprostene bunod 0.024% QD at
8 PM for 14 days in both eyes. The absolute and
change from baseline in sitting IOP was assessed
on day 14.
Results: The mean (SD) age of the subjects was
26.8 (6.3) years, and mean (SD) baseline IOP was
13.6 (1.3)mmHgin the studyeye. Latanoprostene
bunod 0.024% instilled QD for 14 days reduced
IOP at all the evaluated time points (P\0.001)
with a mean (SD) 24-h reduction of 3.6 (0.8)
mmHg or 27% from the baseline in the study eye.
Peak and trough IOP lowering occurred at 8 AM
and8PM(12 and24 h following instillation)with
amean reduction of 4.2 (1.8)mmHg, or 30%, and
2.8 (2.2) mmHg, or 20%, respectively. Punctate
keratitis and ocular hyperemia, both mild in
severity, were the most common adverse events.
Electronic supplementary material The online
version of this article (doi:10.1007/s12325-015-0260-y)
contains supplementary material, which is available to
authorized users.
M. Araie
Kanto Central Hospitals, Mutual Aid Association of
Public School Teachers, Setagaya-Ku, Tokyo, Japan
M. Araie
Department of Ophthalmology, University of Tokyo
School of Medicine, Tokyo, Japan
B. S. Sforzolini
Medical Affairs, Bausch & Lomb Incorporated,
Bridgewater, NJ, USA
J. Vittitow (&)




Hamilton Glaucoma Center, Shiley Eye Institute
and Department of Ophthalmology, University of
California San Diego, La Jolla, CA, USA
Adv Ther (2015) 32:1128–1139
DOI 10.1007/s12325-015-0260-y
Conclusion: Latanoprostene bunod
ophthalmic solution 0.024%, dosed QD for
14 days, significantly lowered mean IOP in
healthy Japanese subjects during the entire
24-h period. Studies of latanoprostene bunod
in patients diagnosed with normal tension
glaucoma are warranted.
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INTRODUCTION
Primaryopen-angle glaucoma (POAG) is a chronic,
progressive, optic neuropathy involving retinal
ganglion cell death and optic nerve degeneration.
Although a number of risk factors are associated
with the development of POAG, including family
history, age, race, intraocular pressure (IOP), and
use of topical or systemic corticosteroids, the
reduction of IOP is the only proven method of
treatment for the disease [1, 2]. Normal tension
glaucoma (NTG) is definedas POAGwith an IOPof
B21 mmHg, and accounts for a significant
proportion of POAG cases, particularly in the
Asian population [3, 4]. The Collaborative
Normal Tension Glaucoma Study demonstrated
that, despite beingwithin the normal range, IOP is
a factor in theopticnervedamageobserved inNTG
and that therapy aimed at lowering IOP is
beneficial in patients at risk of progression [5, 6].
Further studies have suggested that reduced blood
flow, leading to reduced ocular perfusion pressure,
and/or diurnal IOP fluctuation and nocturnal IOP
spikes contribute to disease progression in NTG
[7–10].
Latanoprostene bunod (LBN; Bausch & Lomb,
Inc.) is a single entity nitric-oxide (NO)-donating
prostaglandin F2a receptor agonist in clinical
development for the reduction of intraocular
pressure (IOP) in patients with open-angle
glaucoma or ocular hypertension (OHT). On
topical ocular administration, LBN is rapidly
metabolized by esterases to latanoprost acid, a
prostaglandin analog, and butanediol
mononitrate (BDMN), the nitric oxide
NO-donating moiety. Nitric oxide is subsequently
released from BDMN in conjunction with
1,4-butanediol, an inactive metabolite.
Latanoprost acid, the active moiety present in
Xalatan (latanoprost ophthalmic solution
0.005%), lowers IOP through a mechanism that
mainly involves long-term remodeling of the
extracellular matrices in the ciliary body, thereby
increasinguveoscleral (nonconventional) aqueous
humor outflow [11–15]. Nitric oxide is an
endogenous signaling mediator which has been
shown to lower IOP in clinical and animal models
of OHT [16–21] and has been implicated in IOP
homeostasis inPOAGpatients [22,23].Nitricoxide
is reported tomediate IOP lowering in animal and
ex vivo tissue models through an increase in
conventional (trabecular meshwork and
Schlemm’s canal) aqueous outflow [18, 19,
24–29]. This appears to be mediated though
activation of a signaling cascade involving
elevation of cyclic guanosine 30,
50-monophosphate levels and subsequent
relaxation of the tissues of the conventional
outflow pathway [28–31].
Nonclinical and clinical studies have
demonstrated the contribution of both active
moieties of LBN (latanoprost acid and NO) to its
robust IOP-lowering efficacy, thereby
suggesting a dual mechanism of action for
LBN [32–34]. Krauss et al. demonstrated that
LBN lowered IOP with greater efficacy than
equimolar concentrations of latanoprost in
multiple animal models of elevated IOP [33].
More recently, Cavet et al. reported that LBN
Adv Ther (2015) 32:1128–1139 1129
had a significantly greater relaxation effect on
endothelin-1 contracted human trabecular
meshwork cells than that observed with
latanoprost [32]. Weinreb et al. further showed
that LBN administered once daily (QD) was
effective in lowering IOP in subjects with OAG
or OHT in a dose-dependent manner with LBN
0.024% dose providing statistically significantly
greater reductions in mean diurnal IOP than
latanoprost 0.005% QD (Xalatan) [34].
The objective of the present clinical study,
designated the KRONUS study (Clinicaltrials.gov
identifier: NCT01895985), was to evaluate the
effect of LBN 0.024% dosed QD in reducing IOP
measured over a 24-h monitoring period in
healthy, male Japanese subjects. Determination
of time points for peak and trough IOP lowering
effects were of interest for the design of future
pivotal efficacy studies of LBN in Japanese




a single clinical site located in Japan. The three
study visits occurred in a clinical setting, and all
study procedures were conducted by certified
investigators and/or technicians. All study-related
documents, including the protocol, informed
consent form, and subject recruitment materials
were approved by the Kitasato University Kitasato
Shirogane Institutional Review Board (Shirogane,
Minato-ku, Tokyo, Japan). This study was
conducted in accordance with current
International Conference on Harmonization
(ICH), Good Clinical Practice (GCP) guidelines,
Ministerial Ordinance on GCP for Drugs (JAPAN
GCP), and the Declaration of Helsinki 7th revision
(2013).
Subjects
Subjects who participated in this study were
recruited from a pool of healthy volunteers. All
subjectswere required to bemale, at least 20 years
of age, and be able to self-administer eye drops. A
normalophthalmichistoryandcorrecteddecimal
visual acuity (VA)of 0.5orbetter inbotheyeswere
also required for study enrollment. Subjects were
not allowed to use non-prescription (including
vitamins or dietary supplements) or prescription
drugs 28 days prior to study drug administration
or during the study treatment period (14 days).
Additionally, subjects were excluded from the
study if they had a history of severe ocular trauma
or incisional surgery, a history of ocular laser
surgery (90 days), or had any intraocular
inflammation or infection within 90 days prior
to screening.
Study Treatments and Assessments
All subjects instilled LBN ophthalmic solution
0.024% (manufactured by Bausch & Lomb Inc,
Tampa, FL) QD for 14 days at approximately 8
PM, starting on the evening of day 1 and ending
on the evening of day 14, and completed three
study visits (Fig. 1). Visit 1, the screening visit,
occurred from 1 to 28 days prior to Visit 2, the
baseline visit. At the screeningvisit, subjectswere
evaluated against the inclusion and exclusion
criteria and, if found to be suitable for
enrollment, vital signs, corrected decimal VA, a
slit-lamp examination, IOP measurements, and
ophthalmoscopy assessments were conducted. A
urine sample for drug testing and a blood sample
for serology testing were also collected. At
screening and at all study visits, IOP was
determined in both eyes using Goldmann
applanation tonometry in the sitting position.
Adverse events were collected at all study visits.
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Visit 2, the baseline visit, occurred on days
0–1. Intraocular pressure measurements were
taken at 8 PM and 10 PM, marking the
beginning of the 24-h baseline IOP
measurements. Additional IOP measurements
were taken at 12 AM (marking the beginning of
day 1), 2 AM, 4 AM, 8 AM, 10 AM, 12 PM, and 4
PM. Study drug was dispensed to subjects
following the 4 PM assessment. Prior to
discharge, subjects were instructed to instill
the first drop of study drug into the
conjunctival cul de sac of each eye at
approximately 8 PM on day 1, which was the
start of the treatment period, and were
instructed to record their daily dosing on a
diary card. Both eyes were to be dosed QD at 8
PM for the duration of the study.
Visit 3 was the exit visit, occurring on days
14–15. Subjects returned to the clinic within 1 h
prior to instillation of the final dose at 8 PM in
the clinic on day 14. Intraocular pressure
measurements were taken at approximately
8 PM and 10 PM, marking the beginning of
the 24-h IOP measurements while on
treatment. Additional IOP measurements were
taken at 12 AM (marking the beginning of day
15), 2 AM, 4 AM, 8 AM, 10 AM, 12 PM, and 4
PM. Additional safety assessments at Visit 3
included vital signs (resting blood pressure and
pulse), VA, and slit-lamp examination.
Statistical Methods
The intent-to-treat (ITT) population included all
subjects who received at least one dose of study
drug and had at least one post-baseline IOP
assessment. The safety population included all
subjects who received at least one dose of study
Fig. 1 Schematic of the clinical study design. Three study
visits were required for all subjects to complete the study.
Measurements of intraocular pressure (IOP) were recorded
from both eyes for each subject at Visit 2 and Visit 3 at
nine time points (8 PM, 10 PM, 12 AM, 2 AM, 4 AM, 8
AM, 10 AM, 12 PM, and 4 PM). Latanoprostene bunod
0.024% was provided to all subjects following the 4 PM
IOP assessments at Visit 2, with instructions to instill the
study drug QD at 8 PM
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drug. The per-protocol (PP) population included
all subjects in the ITT population who remained
in the study through Visit 3 (day 14/15) and
who did not have major protocol deviations. It
was assumed that a sample size of 20 evaluable
subjects would provide sufficient data to
evaluate the IOP profile over 24 h using
descriptive statistics.
The absolute and change from baseline
(CFB) in IOP at day 14/15 were summarized
using descriptive statistics (n, mean, SD) for
each assessment time point. In addition, a
paired t test was performed on the CFB (ITT
and PP populations). For the purpose of
evaluating the primary efficacy endpoint (CFB
in IOP at each measurement time point), the
right eye was considered the study eye. A
P value less than or equal to 0.05 was the
threshold for determining statistical
significance. Further, baseline and
post-baseline mean 24-h IOP was calculated
by taking the average of the nine IOP values (8
PM, 10 PM, 12 AM, 2 AM, 4 AM, 8 AM, 10 AM,
12 PM, 4 PM) for each subject’s eyes (study eye
and fellow eye, separately) and determining
the mean (SD) of those. All statistical analyses
were conducted using SAS version 9.1 (SAS
Institute, Inc., Cary NC).
Adverse events (AEs) were summarized using
discrete summaries at the subject and event
level by system organ class and preferred term.
Ophthalmoscopy and slit-lamp examination
measurements were summarized using
descriptive statistics for discrete variables.
Visual acuity was summarized using
descriptive statistics for continuous variables.
Dosing compliance was assessed based on
returned subject diaries using the following
calculation: Percent compliance = 100½
number of instillations received= date of diary½
collection - date of first dose + 1:
RESULTS
Subject Disposition and Demographics
A total of 45 subjects were screened and 24
subjects were enrolled in the study. All enrolled
subjects completed the assessments required for
the three study visits. There were no major
protocol violations; hence the ITT and PP
populations were the same. The mean (SD) age
of the study subjects was 26.8 (6.3) years (range
20–39 years). All subjects were male, as specified
by the study inclusion criteria. Mean (SD) 24-h
baseline IOP was 13.6 (1.3) mmHg in the study
eye and 13.9 (1.3) mmHg in the fellow eye.
All subjects were 81–120% compliant with
dosing instructions based on the information
recorded in the subject diaries. Twenty-two
subjects administered all 14 daily doses and two
subjects administered 13 out of 14 daily doses.
Efficacy Results
The baseline (Visit 2) and post-treatment (Visit
3) mean IOP values for the study eye and treated
fellow eye for subjects in the ITT population are
presented by assessment time point in Fig. 2a, b,
respectively. The mean CFB in IOP values for
the study eye and treated fellow eye is presented
by assessment time point in Fig. 3. Treatment
with LBN 0.024% QD for 14 days significantly
reduced IOP at all time points evaluated
(P\0.001). Mean (SD) 24-h IOP
post-treatment was 10.0 (1.0) mmHg in the
study eye and 10.3 (1.0) mmHg in the treated
fellow eye; the mean (SD) 24-h reduction in IOP
was 3.6 (0.8) mmHg or 27% from baseline in the
study eye, and 3.5 (0.9) mmHg or 25% from
baseline in the treated fellow eye. The peak and
trough IOP lowering effect occurred at 8 AM
and 8 PM (12 and 24 h following instillation)
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with a mean (SD) reduction from baseline in the
study eye of 4.2 (1.8) mmHg, or 30% at peak,
and 2.8 (2.2) mmHg, or 20% at trough,
respectively. Peak and trough IOP lowering
was also observed at 8 AM and 8 PM for the
treated fellow eye, with mean (SD) reductions
from baseline of 4.5 (1.8) mmHg, or 31%, and
2.8 (2.3) mmHg, or 18%, respectively.
Safety Results
No serious adverse events were reported during
the course of the study. A total of 55 ocular and
one non-ocular treatment-emergent adverse
events (TEAEs) were reported. One subject
reported the occurrence of a non-ocular TEAE
during the study (mild upper respiratory
inflammation) that was considered unrelated
to study treatment. The 55 ocular TEAEs
occurred in 22 subjects (28 associated with the
study eye; 27 associated with the treated fellow
eye), and were all determined to be mild; the
majority of ocular TEAEs were judged to be at
least possibly or probably related to the study
drug treatment [study eye 96.4% (27/28), fellow
eye 96.3% (26/27)]. Punctate keratitis and
conjunctival hyperemia were the most
commonly reported adverse events (Table 1).
There were no meaningful changes in vital
signs or VA from screening to Visit 3. Mean (SD)
Fig. 2 Mean intraocular pressure (IOP) over 24 h at baseline and after 2 weeks of treatment with latanoprostene bunod,
0.024% in the study eye (a), and the treated fellow eye (b)
Fig. 3 Change from baseline in mean intraocular pressure
(IOP) over 24 h after 2 weeks of treatment with
latanoprostene bunod, 0.024%. The mean change from
baseline (CFB) ± standard error (mmHg) for the study
eye and the treated fellow eye are depicted. Statistically
signiﬁcant differences were observed at all measured time
points over the 24-h monitoring period for the CFB in
mean IOP assessments in both eyes (P\0.0001; paired
t test)
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systolic/diastolic blood pressure was 111.1
(10.7)/66.9 (9.7) at baseline and 103.9 (10.2)/
61.3 (9.8) post-treatment; mean heart rate was
64.9 (9.7) beats per minute (bpm) at baseline
and 65.8 (11.4) bpm post-treatment. The mean
(SD) corrected decimal VA at baseline was 1.06
(0.35) and 1.08 (0.35) for the study eyes and
fellow eyes, respectively. Post-treatment mean
(SD) corrected decimal VA was 1.04 (0.33) and
1.07 (0.35) for the study eyes and fellow eyes,
respectively.
Ophthalmoscopy and biomicroscopy
findings were normal with few exceptions:
mild papilla in the palpebral conjunctiva in
one subject (both eyes, Visit 3), mild superficial
punctate keratitis in four subjects (both eyes in
three subjects; n = 1 Visit 1, n = 2 Visits 1 and 2,
n = 1 Visit 3), and mild cataract in one subject
at Visit 1 and Visit 3.
Conjunctival hyperemia was graded at
screening and at Visit 3 on a 4-point scale
(none, mild, moderate, severe) with the aid of
photographic standards. At baseline, 79.2% (19/
24) of subjects had no indication of
conjunctival hyperemia, 16.7% (4/24) of
subjects had mild conjunctival hyperemia, and
4.2% (1/24) of subjects had moderate
conjunctival hyperemia. Post-treatment, 45.8%
(11/24) of subjects had no indication of
conjunctival hyperemia and 54.2% (13/24) of
subjects had mild conjunctival hyperemia.
DISCUSSION
The purpose of this single-center, open-label
study (KRONUS) was to evaluate the effect of
LBN 0.024%, a single entity monotherapy,
administered once daily for 2 weeks on IOP
over a 24-h monitoring period as compared to
baseline in healthy Japanese subjects. LBN
significantly lowered mean IOP at all measured
time points over the 24-h period to an overall
mean of 10 mmHg after 2 weeks of treatment.
The effect of LBN included dampening of the
diurnal rise in IOP (8 AM) that was observed at
baseline in both the study and fellow eyes.
Given the importance of IOP fluctuations in the
progression of glaucoma [35, 36], in particular
Table 1 Incidence of ocular treatment-emergent adverse events (safety population)
Latanoprostene bunod 0.024% (N5 24)
Study eye Treated fellow eye
Total number of ocular TEAEs 28 27
Subjects with C1 TEAE, n (%) 21 (87.5) 21 (87.5)
Eye disordersa, n (% of subjects)
Conjunctival hyperaemia 12 (50.0) 12 (50.0)
Punctate keratitis 13 (54.2) 12 (50.0)
Conjunctival disorder 1 (4.2) 1 (4.2)
Eye pain 1 (4.2) 1 (4.2)
Visual acuity reduced 1 (4.2) 1 (4.2)
All subjects who received at least one dose of study drug
TEAE treatment-emergent adverse event
a System organ class preferred terms
1134 Adv Ther (2015) 32:1128–1139
in NTG [37, 38], the sustained reduction of IOP
over 24 h is of note. LBN 0.024% was safe and
well-tolerated by the study population; all
adverse events recorded during the study were
mild in severity, and there was no meaningful
effect on vital signs or visual acuity. Changes in
conjunctival hyperemia were not unexpected as
subjects were administered anesthetic drops
every 2 h prior to IOP measures. Both
anesthetics and prostaglandin analogs may
increase levels of hyperemia.
The Collaborative Normal-Tension
Glaucoma study demonstrated that IOP was a
risk factor for NTG and suggested that IOP
lowering may help reduce the progression of
NTG [5, 6]. Other studies have shown that
progression of visual field damage is slowed in
NTG patients after trabeculectomy which
lowered IOP to \11 mmHg [39, 40]. In the
current study of healthy subjects, overall, a 27%
reduction in IOP was noted over 24-h
monitoring in subjects with a baseline mean
IOP of 13.6 mmHg in the study eye. These
results are promising and warrant the study of
LBN 0.024% in subjects with a diagnosis of
NTG. Further, studies have shown that IOP in
non-glaucomatous eyes of Japanese subjects is
lower as compared to IOP in eyes of subjects
with white or black ethnicity [41, 42]. In this
context, it is noteworthy that in the current
study instillation of LBN resulted in a robust
reduction in IOP, despite the subjects’ low
baseline IOP.
The IOP reduction observed with LBN in the
current study compares favorably to that
observed with other IOP-lowering
monotherapies in either healthy subjects or
patients with NTG. Latanoprost 0.005%
administered QD in the evening was reported
to reduce IOP (mean diurnal or a single daily
measurement) between 15 and 23% in studies
varying from 7 to 24 days duration conducted
in healthy subjects [43–46]. Similarly, QD
administration of latanoprost 0.005% reduced
diurnal or 24-h mean IOP by 14–24% in NTG
patients after 3–12 weeks of treatment [47–54].
Additional studies in NTG patients have shown
a 20% reduction in diurnal IOP after timolol
administered twice daily for 3 weeks [47], a 16%
reduction in 24-h IOP after bimatoprost
administered QD for 8 weeks [54], and a 24%
reduction in IOP (mean of two daytime
measurements) after bimatoprost
administration QD for 2 weeks [55]. Studies
with travoprost QD in NTG patients have
shown an 11% reduction in mean IOP over
24 h after 4 weeks [56] and a 19.4% decrease in
mean IOP measured within 2 h after drug
administration in the evening after 12 weeks
of treatment [57].
CONCLUSION
The results of the present study demonstrate
the ability of LBN 0.024% to provide a robust
IOP lowering over 24 h after 2 weeks of dosing
in healthy subjects. Taken with previously
reported IOP lowering data with LBN 0.024%
in patients with POAG or OHT [34], the results
of the present study suggest the potential of
LBN 0.024% to reduce IOP in glaucoma
patients not only with elevated IOP but also
with IOP in the normal range. Studies of LBN
0.024% in patients diagnosed with NTG are
warranted.
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